BANB.SW Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:30):

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide...

Stats
Dzisiejszy wolumen	45 290.00
Średni wolumen	88 215.00
Kapitalizacja rynkowa	5.93B
EPS	CHF0 ( 2024-03-06 )
Następna data zysków	( CHF0 ) 2024-07-24
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	52.70
ATR14	CHF0.126 (0.16%)

Wolumen Korelacja

Długi: 0.05 (neutral)

Krótki: -0.30 (neutral)

Signal:(52.442) Neutral

Bachem Holding AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bachem Holding AG Korelacja - Waluta/Towar

0.00
( neutral )

0.41
( neutral )

0.00
( neutral )

-0.21
( neutral )

-0.56
( weak negative )

Bachem Holding AG Finanse

Annual	2023
Przychody:	CHF577.32M
Zysk brutto:	CHF176.96M (30.65 %)
EPS:	CHF1.500

FY	2023
Przychody:	CHF577.32M
Zysk brutto:	CHF176.96M (30.65 %)
EPS:	CHF1.500

FY	2022
Przychody:	CHF531.74M
Zysk brutto:	CHF171.28M (32.21 %)
EPS:	CHF1.370

FY	2021
Przychody:	CHF503.23M
Zysk brutto:	CHF166.73M (33.13 %)
EPS:	CHF0.287

Financial Reports:

No articles found.

Bachem Holding AG

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.